First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art prostate cancer imaging tools. The NOBLE Registry is co-supported by Telix and Brussels-based Oncidium Foundation.
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut de Cancérologie de l’Ouest (ICO) in St Herblain, France.
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
Telix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
NCCN Guidelines Updated to Include PSMA-PET Imaging
Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68 PSMA-11.
FDA Approves Phase II Kidney Cancer Therapy Study
Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy, TLX250.
Japanese Prostate Cancer Imaging Study Completes Enrolment
Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa University.
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery (RGS)
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany.
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast cancer.